23/03/2012

Warning Issued Over Co-Codamol Tablets

A warning has been issued by the UK medicines regulator after the wrong strength of tablets was put into some packets of the painkiller co-codamol.

Some packs in batch LL11701, expiry date of September 2014, which should contain 8mg/500mg strength tablets have higher strength 30mg/500mg tablets.

The manufacturer Wockhardt UK Ltd has recalled the batch.

The medicine is used as a painkiller for the short term treatment of acute, moderate to severe pain which cannot be relieved by paracetamol, ibuprofen or aspirin alone. It contains codeine.

Ian Holloway, MHRA head of the Defective Medicines Report Centre said: "If you have a packet of the affected medicine, return it to your pharmacist who will replace it.

"If you think you have taken the wrong strength tablet, and in the unlikely event that you feel unwell, speak to your pharmacist or GP promptly."

The strength of the tablets can be identified by their markings.

The 8mg/500mg tablets are marked on one-side only as "" - these can be bought over-the-counter.

However the higher strength 30mg/500mg tablets - marked on one side as "CCD30" and marked as "CP" on the second side - are a prescription-only medicine.




Related UK National News Stories
Click here for the latest headlines.

09 July 2004
Teacher training going from strength to strength
Teacher training continues to go from strength to strength with most new teachers satisfied that their training was good, the Teacher Training Agency (TTA) said today.
01 December 2003
Single-dose 'morning after' pill introduced
The dosage for the emergency 'morning after' pill has been changed to offer more benefits to users "without compromising the drug's safety or effectiveness", the health department has said.
26 August 2011
Anti-Psychotic Drugs 'Swapped With Nurofen'
A British healthcare regulator has issued a public health warning after packets of Nurofen painkillers were found to contain anti-psychotic drugs.
24 May 2006
Herceptin granted UK license
Breast cancer drug Herceptin has been licensed for use in the early stages of the disease in the UK by the European Medicines Agency. The drug, which is already used in Britain to treat the later stages of breast cancer, will now be appraised by the National Institute of Health and Clinical Excellence to see if it is safe and cost-effective.
17 August 2004
New plans to focus on providing better medicines for children
A new initiative to encourage the development of more medicines designed specifically for use in children has been announced today by the government. The new paediatric medicines strategy is aimed at encouraging manufacturers of medicines to research and develop medicines geared to the needs of children.